ABC-CT	Autism Biomarker Consortium for Clinical Trials
AMD	Adjusted mean difference
AMP Schizophrenia	Accelerating Medicines Partnership for Schizophrenia
BACS	Brief Assessment of Cognition in Schizophrenia
BNSS	Brief Negative Symptoms Scale
BOLD	Blood oxygen level-dependent
CANTAB	Cambridge Neuropsychological Test Automated Battery
CBD	Cannabidiol
CFR	Code of Federal Regulation
CGI-S	Clinical global impression of severity of illness
CIAS	Cognitive impairment associated with schizophrenia
CSF	Cerebrospinal fluid
d	Cohen effect size
DAAO	D-amino acid oxidase
EOS	End of study
EPS	Extrapyramidal side effects
FDA	Food and Drug Administration
FNIH	Foundation for the National Institutes of Health
GAF	Global Assessment of Functioning
LAI	Long-acting injectables
LSMD	Least square mean difference
LSMD	Least square mean difference
MAOI	Monoamine oxidase inhibitor
MATRICS	Measurement and Treatment Research to Improve Cognition in Schizophrenia
MCCB	MATRICS consensus cognitive battery
NAC	N-acetylcysteine
NEC	New chemical entities
OLZ	Olanzapine
PANSS	Positive and Negative Syndrome Scale
PEC	Positive and negative syndrome scale excited component
PGRN	Pharmacogenomics Research Network
PMC	Personalized Medicine Coalition
PT	Patients
QOLS	Quality of life scale
RCTs	Randomized controlled trials
SAD	Schizoaffective disorder
SAM	Samadorphin
SANS	Scale for the assessment of negative symptoms
SAR	Sarcosine
SB	Sodium benzoate
SCZ	Schizophrenia
SE	Standard Error
SGA	Second generation antipsychotic
SMD	Square mean difference
TAAR	Trace amine-associated receptors
TEAE	Treatment-emergent adverse effects